IMpower133 — Atezolizumab With Carboplatin and Etoposide in Extensive-Stage Small Cell Lung Cancer (IMpower133)

Phase 3 · 2018 · Small Cell Lung Cancer

Design

Randomized double-blind trial of atezolizumab plus carboplatin-etoposide versus placebo plus carboplatin-etoposide, followed by atezolizumab maintenance.

Population

Treatment-naive extensive-stage small cell lung cancer.

Primary Endpoint

overall survival (OS) and investigator-assessed PFS

Key Result

OS 12.3 vs 10.3 months (HR 0.70), the first practice-changing immunotherapy advance in SCLC in decades.

Guideline Impact

NCCN category 1 atezolizumab plus carboplatin-etoposide for extensive-stage SCLC